Blue Ocean Capital joins Torrey Pines Medicine tens-of-millions-of-RMB angel round

• Shenzhen Blue Ocean Private Equity Investment Management invested in Torrey Pines Medicine in a tens-of-millions-of-RMB angel round.
• Torrey Pines Medicine is a Shenzhen-based biotech developing ultra-long-acting peptide drugs for metabolic diseases, including obesity and type 2 diabetes.
• Proceeds target IND filing and Phase I work for lead asset TPM004, an ultra-long-acting amylin/calcitonin receptor dual agonist.
• Funding also supports expansion of the PepTetris peptide discovery platform, which aims to enable once-monthly or longer-duration dosing.
• Lotus Lake Ventures led the round; Stars Capital, Tainuo Capital, Blue Ocean Capital, and Yousheng Shen participated.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Blue Ocean Private Equity Investment Management Ltd published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.